The im portance of D-E-R characterisation in dose selection, - - PowerPoint PPT Presentation

the im portance of d e r characterisation in dose
SMART_READER_LITE
LIVE PREVIEW

The im portance of D-E-R characterisation in dose selection, - - PowerPoint PPT Presentation

The im portance of D-E-R characterisation in dose selection, labelling and B/ R Children EMA EFPI A w orkshop on the im portance of dose finding and dose selection for the successful developm ent, licensing and lifecycle m anagem ent of m


slide-1
SLIDE 1

The im portance of D-E-R characterisation in dose selection, labelling and B/ R Children

Anne Brochot | 05 December 2014

EMA EFPI A w orkshop on the im portance of dose finding and dose selection for the successful developm ent, licensing and lifecycle m anagem ent of m edicinal products

slide-2
SLIDE 2

2

Pediatric study decision tree

Manolis et al. 2011

slide-3
SLIDE 3

3

Pre-requisite

  • Knowledge of the D-E-R in adults

– Might not be well understood at the time of the PIP development – Case of pediatric specific drugs

slide-4
SLIDE 4

4

Maxim ising the D-E-R know ledge

  • Use of all available knowledge

– What should be included for extrapolation

  • Same class of drug

– Possibility to share models and go for simpler study

  • Use of pre-clinical models

– How much weighting ?

  • Flat D-E-R
slide-5
SLIDE 5

5

Facing the reality of enrollem ent difficulty ( 1 / 2 )

  • Standard study design for all countries
  • How regulators can support industry in

recruitment difficulty

  • Guidance on the number of subject

– is Wang et al. paper enough ? – how much safety is needed ?

  • Integrated Ph I-II-III study (study combining

PK and safety)

slide-6
SLIDE 6

6

Facing the reality of enrollem ent difficulty ( 2 / 2 )

  • Acceptance of innovative design based on M&S, adaptive design

using:

– Efficacy – Safety – Pharmacokinetics

  • Is a full D-E-R characterisation needed ?
  • Group specifities

– Are adolescents part of pediatric population

  • Conduct an open-label safety study in a pediatric population*

– DB is cleanest to show efficacy and safety – Not many subjects to enroll – How ethical is to expose limited population to placebo – Increases safety database – Virtual comparison (simulations) of drug and placebo (disease progression model) as in DB study

Berde CB et al. 2012

slide-7
SLIDE 7

7

Open questions

  • How can we ensure that we don’t miss the opportunity to

make the adult development data also useful for paediatric development ?

  • How to ensure a state of the art paediatric development ?
  • In phase with recruitment reality
  • How do we best support the generation of system data ?